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Background: Stomach cancer is one of the leading causes of cancer deaths in Japan. The objectives of this study
were to estimate and project the economic burden associated with stomach cancer in Japan, and to identify the
key factors that drive the economic burden of stomach cancer.
Methods: We calculated Cost of illness (COI) of 1996, 2002, 2008, 2014 and 2020 by using government office
statistics and the COI method. We calculated direct cost and indirect cost (morbidity cost and mortality cost), and
estimated the COI by summing them up.
Results: The number of deaths remained at approximately 50,000 in 1996–2008. COI was in downward trend from
1,293.5 billion yen in 1996 to 1,114.2 billion yen in 2008. Morbidity cost was 85.6 billion yen and 54.0 billion yen,
mortality cost was 972.3 billion yen and 806.4 billion yen, and mortality cost per person was 19.4 million yen and
16.1 million yen in 1996 and 2008, respectively. Decrease of mortality cost that accounted for a large part of the
COI (72.4% in 2008) was the major contributing factor. COI is predicted to decrease if the trend of health related
indicators continues (442.8-1,056.1 billion yen depending on the model in 2020). Mortality cost per person is also
predicted to decrease (9.5-12.5 million yen depending on the model in 2020).
Conclusions: If the trend of health related indicators continues, it is estimated that COI of stomach cancer would
decrease. “Aging”, “change of the healthcare providing system” and “new medical technology” are considered as
contributing factors of COI.
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Stomach cancer (ICD 10 cord: C16) was the leading
cause of cancer deaths in Japan, but recently its mortal-
ity rate has been decreasing. The age-adjusted mortality
rate has been continuously decreasing from 56.9 in 1975
to 18.1 in 2010[1]. The age-adjusted morbidity rate has
also been continuously decreasing. It decreased from 84.0
in 1975 to 51.3 in 2007 [1]. However, the number of
deaths during these two periods has remained the same
and approximately 50,000 people die of stomach cancer
every year. In 2009 stomach cancer accounted for 14.5%
of all cancer deaths. Stomach cancer was the 2nd leading
cause of cancer deaths next to lung cancer in men and the
3rd leading cause of deaths next to colon cancer and lung
cancer in women in Japan. Even today, mortality rate of* Correspondence: tommie@med.toho-u.ac.jp
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reproduction in any medium, provided the orstomach cancer remains high. Furthermore, according to
“Survey of National Medical Care Insurance Services”, the
medical expenses due to the stomach cancer treatment
accounted for approximately 10% of the medical expenses
of all cancers in 2009.
Stomach cancer is a disease of high morbidity rate in
the elderly, and with Japan’s acceleration into an aging
society, the economic burden related to stomach cancer
is considered to be changing dramatically. However, only
a few articles estimate its economic burden in Japan.
Most of them, moreover, are limited to the estimation
of direct medical expenses, only in one time-point or
cost-effectiveness of Helicobacter pylori eradication [2-4].
Koinuma estimated that cost (direct cost, morbidity cost
and mortality cost) of stomach cancer was approximately
1,400 billion yen in 2005 [3]. The incidences of stomach
cancer differ greatly by country. It is known to be high in
Japan and to be low in the United States and Europe. Lowtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Haga et al. BMC Health Services Research 2013, 13:283 Page 2 of 9
http://www.biomedcentral.com/1472-6963/13/283incidence and limited social burden might explain for
the scarcity of studies about cost of stomach cancer in
those countries. Furthermore there are few long-term
estimations or future predictions of economic burden
of stomach cancer.
The objectives of this study were to estimate and pro-
ject the economic burden associated with stomach can-
cer in Japan, and to identify the key factors that drive
the economic burden of stomach cancer.
Methods
Analysis method
In this study, we used government office statistics and
the Cost of illness (COI) method developed by Rice DP
to estimate burden of disease [5-10].
The COI consists of direct cost (DC) and indirect cost
(IC). Indirect cost consists of morbidity cost (MbC) and
mortality cost (MtC). COI is calculated using following
equations:
COI ¼ DCþMbCþMtC Direct cost
The direct cost is defined as medical expenses
(treatment costs, hospital charges, laboratory costs,
drug costs, etc.). In this study, we used “Survey of
National Medical Care Insurance Services”, and
calculated annual medical expenses based on
reimbursement data.
 Indirect cost
The indirect cost is an opportunity cost lost by
contraction of a disease and the death. They are
calculated using following equations:
MbC ¼ TOVy  LVd=2þ THD LVd
MtC ¼ NDy  LVl
Where: TOVy is total person-days of outpatient
visit, LVd is one day labor-value per person, THD is
total person-days of hospitalization, NDy is the
number of deaths, and LVl is lifetime labor-value
per person.
Total person-days of outpatient visit and
hospitalization according to sex and 5 years age
groups were calculated based on “Patient Survey”.
The labor-value was calculated according to sex and
5 years age groups by using “Basic Survey on Wage
Structure”, “Labor Force Survey” and “Estimates of
monetary valuation of unpaid work” [11]. Lifetime
labor-value was calculated by summing up the
income which they could have earned in the future
if they had not died. We calculated the morbidity
cost by assuming that one day labor-value loss forone hospitalized day and a half day labor-value loss
for one outpatient visit. We used the number of
deaths by stomach cancer according to sex and
5 years age groups from “Vital Statistics”. LVd and
THD were obtained as follows:
LVd ¼ Iy þ ULVyð Þ=365
THD ¼ HPy  ALOS
Where: Iy is annual income per person, ULVy is
annual monetary valuation of unpaid work per
person, HPy is the number of annual hospitalized
patients, and ALOS is average length of stay.
We assumed an average life expectancy for their life
span. Future labor-value was adjusted to a present
value using 3% discount rate, because 3% is widely
used as discount rate in the United States, where the
application of the COI method was popular.Examination element
The following 8 elements were considered to affect COI;
(1) number of times of outpatient visits, (2) number of
times of hospitalization, (3) average length of stay, (4) num-
ber of deaths, (5) human capital value, (6) medical technol-
ogy, (7) income, (8) discount rate used to calculate lifetime
income. They seem to interact with one another. In this
study, we tried to make clear the factors relating to COI by
examining these elements. As for (6), we used only fatality
rate calculated from morbidity rate and mortality rate as an
indicator of medical technology only for discussion since it
was not used for calculation of COI, and the change of spe-
cific treatment regimen was not taken into consideration.
Time series estimation of COI
At first, using available past data, we estimated COI in
1996, 2002 and 2008. Then, we predicted COI in 2014
and 2020 using two methods.
The first method was “fixed model estimation”, that
is, the estimation that assumed health related indicators
(mortality rate, number of times of outpatient visit per
population, number of times of hospitalization per popu-
lation, and average length of stay) were fixed. We used
those values at 2008, and only future population estima-
tion was used as a variable. First, we calculated mortality
rate, number of times of outpatient visit per population,
and number of times of hospitalization per population
according to sex and 5 years age groups at 2008 as indica-
tors of the standard year. Next, by multiplying them
with the future population estimates according to sex
and 5 years age groups of 2014 and 2020, we calculated
the predictive number of deaths, total person-days of
outpatient visit, and total person-days of hospitalization
in 2014 and 2020. We estimated the morbidity cost and
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age length of stay, life expectancy and labor-value at 2008.
Direct costs were calculated by multiplying the cost of
outpatient visit and hospitalization expenses at 2008 with
the rate of change of the total number of days of out-
patient visit and hospitalization of 2014 and 2020.
The second method was “variable model estimation”,
that is, the estimation where health related indicators
changed at the same pace as in the past 12 years, in
addition to the change of population and age structure.
First, we drew the trend line (a logarithm approximation
and a linear approximation) since 1996 of each indicator,
respectively. Next we calculated the value of the 2014 and
2020 using the trend line formula. We used three variable
models according to the approximation: 1. Logarithm
model; health related indicators were calculated using aTable 1 The elements used for calculation in future prediction
Model Item Elements used for calc
Fixed model
Number of deaths Mortality rate
The population estimates
Direct cost The expenses of outpatient visit an
Total person-days of outpatient vis
Total person-days of hospitalizatio
Morbidity cost Number of times of outpatient vis
Number of times of hospitalization
Average length of stay
The population estimates
Labor-value








Number of deaths Mortality rate
The population estimates
Direct cost The expenses of outpatient visit an
Total person-days of outpatient vis
Total person-days of hospitalizatio
Morbidity cost Number of times of outpatient vis
Number of times of hospitalization
Average length of stay
The population estimates
Labor-value




Fixed: The value of 2008 was used. Varied: The values of 2014 and 2020 were calculogarithm approximation. 2. Linear model; health related
indicators were calculated using a liner approximation.
3. Mixed model; an approximation with the higher co-
efficient of determination. The elements used for calcu-
lation in future prediction of COI are shown in Table 1.
2008 data was used for life expectancy and the labor-
value. In addition, we used 1996, 2002 and 2008 “Popu-
lation estimates” by Ministry of Internal Affairs and
Communications, and 2014 and 2020 “Population statis-
tics of Japan” by National Institute of Population and
Social Security Research.
When estimating using the trend line, a future pre-
dicted value sometimes took less than 0. Therefore, we
needed to set a “minimum value”. For mortality rate, num-
ber of times of outpatient visit per population and number
of times of hospitalization per population, the previous valueof Cost of illness (COI)
ulation Fixed or Varied
Fixed
Varied
d hospitalization Fixed (Calculated using the unit cost in 2008)
it Varied
n Varied




Fixed (one day labor-value loss for one hospitalized day





Varied (Calculated using the trend line formula)
Varied
d hospitalization Fixed (Calculated using the unit cost in 2008)
it Varied
n Varied
it per population Varied (Calculated using the trend line formula)
(minimum value: the previous value before 0)
per population Varied (Calculated using the trend line formula)
(minimum value: the previous value before 0)
Varied (Calculated using the trend line formula)
(minimum value: 8.2days)
Varied
Fixed (one day labor-value loss for one hospitalized day





lated based on the trend line.
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minus values. As for average length of stay, we set 8.2 days-
the average length of stay of patients with malignant neo-
plasm (2006) of OECD 28 countries- as “minimum value”.
In Japan, the average length of stay of stomach cancer
(26.8 days) was similar to that of the whole malignant
neoplasm (23.9 days) according to “Patient Survey”.
Results
Result of the estimation of time series COI in 1996, 2002
and 2008
COI was estimated at 1,293.5 billion yen in 1996, 1,234.4
billion yen in 2002 and 1,114.2 billion yen in 2008. Com-
paring 1996 and 2008, COI decreased by 13.9%. According
to “Patient Survey”, the number of total patients with
stomach cancer has been decreasing; 305,000 people in
1996, 222,000 in 2002 and 213,000 in 2008. And the aver-
age length of stay has been shortening; 47.1 days, 39.3
days and 26.8 days, respectively. The number of deaths
has not changed so much, but the average age of deaths
has been gradually rising, and the proportion of deaths of
65 years or older among the whole deaths has increased
(Table 2). Fatality rate of both sexes has decreased possibly
reflecting the progress of the recent medical technologies.
However, fatality rate of elderly people was higher than
that of young people, and decreased less compared to that
of young people (fatality rate of people aged 65 or older
was 0.63 in 1996 and 0.58 in 2002, and that of people agedTable 2 The time trend of Cost of illness (COI) of stomach can
Item
Population (thousand person)
[% of 65 years or older]
Number of stomach cancer deaths (person)
[% of 65 years or older]
Average age of death (year)
Crude morbidity rate (per 100 thousand) male
female




Direct cost (billion yen)
Morbidity cost (billion yen)
Mortality cost (billion yen)
[% of 65 years or older]
Mortality cost per person (million yen)
COI (billion yen)
Source of population:Ministry of Internal Affairs and Communications “Population E
Source of the number of stomach cancer deaths: “Vital Statistics”.
Average age of death: Calculated according to the number of deaths, sex and age
Source of crude morbidity rate and crude mortality rate:Center for Cancer Control a
Fatality rate:We calculated by dividing the crude mortality rate by crude morbidity
NA: not available64 or younger was 0.40 in 1996 and 0.34 in 2002). The dir-
ect cost has increased a little, but morbidity cost and mor-
tality cost have decreased. The mortality cost per person
(mortality cost divided by number of deaths) has de-
creased. In mortality cost, the proportion of 65 years or
older has increased.
Result of the estimation of COI in 2014 and 2020
(fixed model)
Future projection of Japanese population (medium esti-
mate) by National Institute of Population and Social Secur-
ity Research predicted a gradual decrease (127.6 million
in 2008, 125.9 million in 2014 and 122.7 million in
2020), and a proportion of 65 years old or older was
predicted to gradually increase (22.1%, 26.2% and 29.2%,
respectively) [12](Table 3). The number of deaths of stom-
ach cancer was expected to increase by 31.9% from 2008
to 2020. Specifically the number of deaths of elderly
people (65 years or older) increases remarkably, and it
occupies 87.2% of all stomach cancer deaths in 2020.
The average death age was expected to rise. The mor-
tality cost per person showed downward tendency. The
proportion of 65 years or older would occupy 50.0% of
all mortality cost in 2020. In the fixed model, direct
cost, morbidity cost and mortality cost would increase,
and we estimated that COI would increase by 9.8%
from 2008 to 2020 (1,177.4 billion yen in 2014 and




















(5 years old age-grade), cause of death in “Vital Statistics”.
nd Information Services, National Cancer Center, Japan.
rate.
Table 3 Future prediction of Cost of illness (COI)
Model Item 2008 2014 2020
Estimated population (thousand person) 127,690 125,862 122,735
[% of 65 years or older] 22.1% 26.2% 29.2%
Fixed model
Number of stomach cancer deaths (person) 50,156 58,784 66,164
[% of 65 years or older] 80.7% 84.7% 87.2%
Average age of death (year) 74.1 75.5 76.6
Direct cost (billion yen) 253.7 288.0 315.3
Morbidity cost (billion yen) 54.0 56.1 57.3
Mortality cost (billion yen) 806.4 833.4 851.7
[% of 65 years or older] 42.0% 47.3% 50.0%
Mortality cost per person (million yen) 16.1 14.2 12.9
COI (billion yen) 1,114.2 1,177.4 1,224.3
Variable model
Logarithm model
Number of stomach cancer deaths (person) 50,156 58,554 62,868
[% of 65 years or older] 80.7% 84.9% 87.7%
Average age of death (year) 74.1 75.6 76.9
Direct cost (billion yen) 253.7 243.8 227.9
Morbidity cost (billion yen) 54.0 49.3 42.4
Mortality cost (billion yen) 806.4 824.4 785.8
[% of 65 years or older] 42.0% 47.5% 51.0%
Mortality cost per person (million yen) 16.1 14.1 12.5
COI (billion yen) 1,114.2 1,117.5 1,056.1
Linear model
Number of stomach cancer deaths (person) 50,156 45,021 37,581
[% of 65 years or older] 80.7% 87.1% 91.8%
Average age of death (year) 74.1 76.7 79.1
Direct cost (billion yen) 253.7 162.3 67.3
Morbidity cost (billion yen) 54.0 31.0 17.7
Mortality cost (billion yen) 806.4 557.0 357.7
[% of 65 years or older] 42.0% 52.5% 60.7%
Mortality cost per person (million yen) 16.1 12.4 9.5
COI (billion yen) 1,114.2 750.3 442.8
Mixed model
Number of stomach cancer deaths (person) 50,156 45,021 37,581
[% of 65 years or older] 80.7% 87.1% 91.8%
Average age of death (year) 74.1 76.7 79.1
Direct cost (billion yen) 253.7 187.1 100.4
Morbidity cost (billion yen) 54.0 37.1 26.4
Mortality cost (billion yen) 806.4 557.0 357.7
[% of 65 years or older] 42.0% 52.5% 60.7%
Mortality cost per person (million yen) 16.1 12.4 9.5
COI (billion yen) 1,114.2 781.2 484.5
Source of estimated population:2008;Ministry of Internal Affairs and Communications “Population Estimates” 2014•2020;National Institute of Population and Social
Security Research “Population Statistics of Japan”.
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(variable model)
Figures 1 and 2 show the trends of COI of each model. Any
model but the fixed model showed a downward tendency.
Future prediction of COI is shown in Table 3. In the loga-
rithm model, the number of predictive deaths increased,
however, the number was less than that of the fixed model.Direct cost and morbidity cost decreased continuously, and
mortality cost increased in 2014, but decreased in 2020. As
a result, COI also increased to 1,117.5 billion yen in 2014,
but decreased to 1,056.1 billion yen in 2020.
In the linear model, the number of predictive deaths was
estimated to show a decrease. Direct cost, morbidity cost,




















Figure 1 The time trends of Cost of illness (COI) by prediction models.
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yen in 2014 and 442.8 billion yen in 2020.
Since the trend of each health related indicator was
different, the monotype estimation (both logarithmic model
and linear model) might not predict future COI precisely.
Therefore we developed a mixed model where we adopted
value with higher coefficient of determination in each age
group. In the mixed model, the logarithm approximation
was used for number of times of outpatient visit and num-









1996 2002 2008 2014 2020 2014 20




Figure 2 Cost of illness (COI) projection with cost element.linear approximation was used for average length of
stay and mortality. This adaptation was made to equal
the number of deaths and mortality cost to those of the
linear model. In the mixed model, COI was estimated
to decrease to 781.2 billion yen in 2014 and 484.5 billion
yen in 2020, and it decreased by 56.5% from 2008 to 2020.
Number of deaths, direct cost, morbidity cost, mortality
cost and COI showed downward trend from 2008, and
were estimated to be less than those of the logarithm
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older amounted to 91.8% of all deaths, and average age
of death rose to 79.1 years old. Also the mortality cost
per person showed remarkable decline (9.5 million
yen), and the proportion of mortality cost of 65 years
or older would account for 60.7%.Discussion
We found that COI was in downward trend from 1996
to 2008. As for future projection, only the fixed model
suggested a slight increase of COI. With the variable
models where health related indicators’ change was taken
into consideration, COI was expected to decrease. Specif-
ically, the mixed model suggested continuous decrease of
the number of deaths, direct cost, morbidity cost, mortal-
ity cost and COI. Since the mixed model was a combin-
ation of models of higher coefficient of determination, it
was considered that the mixed model was the most valid
model for our study.
In our analysis, the main model is the mixed model.
The fixed model is a reference. The logarithm model is
the low-end, and the linear model is the high-end estima-
tion, respectively, and they can be regarded as sensitivity
analyses showing the robustness of the mixed model.
Aging population, change in providing system, and
change in medical technology could affect COI. We ob-
served (1) decrease of number of times of outpatient
visit per population, (2) decrease of number of times of
hospitalization per population, and (3) shortening of
average length of stay, which could all have contributed
to the decrease of COI.
Japanese society has been aging rapidly in recent years.
Among elderly people, morbidity and mortality of stom-
ach cancer were high, and health related factors were also
related to aging. For example, fatality rate of the elderly
people was high and had decreased less compared to that
of young people, and “aging” contributed to increase the
number of deaths of stomach cancer in total. On the other
hand, labor- value of elderly people was low, and human
capital value per person was low, thus contributing to
decreased mortality cost. Recent COI decrease can be
explained by the balance between “decrease of human
capital loss by decreased number of deaths in young
people” and “increase of the human capital loss by in-
creased number of deaths in elderly people”.
Furthermore, “aging” is predicted to accelerate in the
future [12]. This will affect future COI. The fixed model
showed that all of the number of predictive deaths, dir-
ect cost, morbidity cost, mortality cost and COI would
increase in the future. Even though the number of deaths
was estimated to increase by 31.9% from 2008 to 2020,
mortality cost was estimated to increase only by 5.6%. Eld-
erly people aged 65 years or older would occupy asignificant portion of deaths (80.7% in 2008, 87.2% in
2020). Mortality cost per person would decrease since the
human capital value would decrease according to age of
deaths (16.1 million yen in 2008, 12.9 million yen in
2020). Although mortality cost would increase by the
rapid increase of the number of deaths especially in elderly
people, the increase rate of the total mortality cost would
remain low.
In the mixed model, it was estimated that all of the
number of predictive deaths, direct cost, morbidity cost,
mortality cost and COI would decrease in the future. The
number of deaths would decrease by 25.1%, and mortality
cost would decrease by 55.6% from 2008 to 2020. Com-
pared with the fixed model and the logarithm model, in-
crease of the proportion of the elderly people among all
deaths (80.7% in 2008, 91.8% in 2020), rise of the average
death age, decrease of mortality cost per person (16.1
million yen in 2008, 9.5 million yen in 2020) predicted
in this model were remarkably different. The fact that the
number of deaths in young people whose human capital
value was high decreased significantly may be considered
to have caused the decrease of the total mortality cost.
Recently, the Japan Ministry of Health, Labor and
Welfare introduced several policies as a part of a health
sector reform [13]. Most policies aimed at cost-efficient
care by containing hospital use. Among them, the intro-
duction of DPC/PDPS (Diagnosis Procedure Combination/
Per Diem Payment System) in 2003 encouraged hospitals
to shorten length of hospital stay. With DPC/PDPS, hospi-
tals with longer length of hospital stay were paid less
money, and hospitals reimbursed by DPC/PDPS were
likely to introduce clinical pathways, increase the use of
outpatient department for diagnostic tests, procedures
and chemotherapies, and further establish network with
other step-down facilities to shorten length of stay [14].
New medical technologies have made outpatient treat-
ment of stomach cancer possible. More and more stom-
ach cancer patients are being treated as outpatients and in
their homes. In this study, a slight increase was observed
in number of times of outpatient visit per population from
2005 to 2008. Although specific medical technologies
were out of the scope of this study, containment of hos-
pital use and development of new technologies could
contribute to the little change or the increased use of
outpatient services.
The results of this study suggested that the decrease of
the human capital value by aging was the main factor of
the change of COI in stomach cancer and other factors
such as healthcare providing system and new medical
technologies could also influence COI. Although aging
of the society cannot be controlled in the near future,
the latter two can be manipulated by a change in health
policy and progress of medical technology. Therefore, the
detailed and continuous analyses of these are important.
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was used in our study since it has been used widely to
evaluate the burden of disease since 1960s, and has been
used for policymaking [15-19]. There are reports that
the COI method has been used in several countries and
international organization [20,21]. On the other hand,
there is also the criticism against the COI method that
COI studies can be used for advocacy purposes and it
cannot be used for policy making or decision-making
[22]. We consider that the COI method is suitable for
time series comparison and future prediction of the eco-
nomic burden because of its simplicity, admitting the
availability and effectiveness in policy-making are still to
be demonstrated. Among the other limitations is how a
value of estimations using approximate curves reflects
real situation in predicting the future. We should be
careful in interpreting the outcome since the data used
were collected from a relatively short term during the
period between 1996 and 2008. The appropriateness of
setting the “minimum value” should also be examined.
Long term insurance was introduced in 2000, and shift
of healthcare expenditure from medical insurance to
long term insurance occurred. This study dealt with COI
of stomach cancer, and assuming most patients were
being treated by medical insurance, cost of long term
insurance was not taken into account. In some chronic
diseases, cost of long term insurance should be in-
cluded in COI. Furthermore, in the COI method, it is
difficult to consider the quality of life of the patients,
and it is also difficult to include a change of utility and
efficiency of a specific treatment into analysis.
The COI method enables to clarify how to use the lim-
ited health resources effectively and supports rational
decision making by measuring a burden of disease by
monetary term [6]. It can justify intervention plan and
provide basic information for policy making in the pre-
vention and management of the disease [10].
Cancer has become the leading cause of death in Japan
since 1981. It is not just a serious problem in the life and
health of a people, but its economic burden should also be
considered. The government took action by implementing
various cancer control programs beginning with “Ten-year
General Anti-cancer strategy” (1984). The degree of con-
tribution or the resulting effects on the population by
each governmental cancer control program could not
be assessed by this study, but mortality and COI of
stomach cancer has been in the tendency to decrease.
In recent years, as the measure for stomach cancer con-
trol, Helicobacter pylori eradication and new screening
method were introduced [23,24]. There are several studies
reporting economic effects of Helicobacter pylori eradica-
tion [4,25], and Helicobacter pylori eradication might re-
duce healthcare cost of stomach cancer. Our study does
not take the effect of a specific treatment technology intoconsideration, and further study of COI including the
possible effect of Helicobacter pylori eradication treat-
ment would be needed.
Conclusions
We confirmed that the future prediction of COI of
stomach cancer was possible by using government office
statistics. COI was in a downward trend from 1996 to
2008. If the trend of health related indicators continue,
it is estimated that COI of stomach cancer would decrease.
“Aging”, “change of the healthcare providing system” and
“new medical technology” are considered as contributing
factors of COI, and in particular, it was revealed that
the decrease of the human capital value by aging has sa-
lient influence on the COI. It is anticipated that future
studies of COI of stomach cancer to include the targeted
effects of new cancer control programs to enable prioritiz-
ing implementation of new policies and the development
of medical technologies.
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